news.harvard.edu — In a demonstration that even some of the most hard-to-treat tumors may one day succumb to therapies aimed at molecular ?weak points,? researchers at Dana-Farber Cancer Institute report the first instance in which metastatic melanoma has been driven into remission by a targeted therapy.
Apr 28, 2008 View in Crawl 4
esantipapaApr 28, 2008
Please write to congress about my COUSIN CARMELO RODRIGUEZ!!!There is a template letter here: (no rickroll)<a class="user" href="http://carmelofoundation.chipin.com/carmelo-foundation">http://carmelofoundation.chipin.com/carmelo-founda ...</a><a class="user" href="http://digg.com/world_news/A_Question_Of_Care_Military_Malpractice_Kills_Marine">http://digg.com/world_news/A_Question_Of_Care_Mili ...</a><a class="user" href="http://digg.com/world_news/Sgt_Carmelo_Rodriguez_melanoma">http://digg.com/world_news/Sgt_Carmelo_Rodriguez_m ...</a>Digg if you care. Thank you very much!!
bbqsaladApr 28, 2008
buried actually...
drdragunApr 28, 2008
A risky claim to make when you are posting from the SatPhonePing to koft: 348730 ms
nullcodesApr 28, 2008
Multi-target therapy is used to overcome resistance. That is a drugs that can attack three or four targets simultanously.This will be how cancers in the future are treated.1. A sample of a person's cancer is sequenced. 2. At least four targeted drugs are given that each of which target mutations found in the person's tumor.Provide all the drugs penetrate and are consistently bioavailable, for the tumor to become resistant, at least one tumor cell will need to generate an offspring that has at all four mutations simultaneously .. each of which enable evasion of the drugs. Resistance arises because given the large number of tumor cells .. it is probable that some of the cells and also their offspring cells contain a mutation (or mutations) in exactly the right spot so that the drug target is modified to evade the drug. However it is highly unlikely that a cell or its offspring would have mutations in exactly the right locations to evade 3 or 4 drugs simultaneously (giving 3 drugs in sequential monotherapy fails because given that the first drug may leave behind millions of cells .. a large number of _those_ cells an offspring is very likely to be mutant to the second drug also).In the more distant future .. step two will be one drug that attacks multiple targets .. so the tumor cell needs far too many exacting simultaneous SNPs. This will overcome a top reason combination therapy can fail in diseases like AIDS .. which is that each drug is differently bioavailable and then it becomes the same as sequential monotherapy which is inevitably doomed to failure.Gleevec + Dasatinib simultaneously is very effective in curing CML in most people because it covered nearly all possible mutations (except one .. therefore it doesn't cure everyone).
nullcodesApr 28, 2008
Hey look into this:<a class="user" href="http://www.medpagetoday.com/HematologyOncology/Leukemia/tb/6437">http://www.medpagetoday.com/HematologyOncology/Leu ...</a>
Closed AccountApr 28, 2008
holy s**t I thought it said "meglomania"